Please note, this OEL/ADE monograph also applies to ondansetron hydrochloride (CAS RN 99614-01-4) and ondansetron hydrochloride dihydrate (CAS RN 103639-04-9). Ondansetron is indicated for the prevention of chemotherapy-induced nausea and vomiting, postoperative nausea and vomiting, and radiation-induced nausea and vomiting. The mechanism of action of ondansetron is not completely understood. Chemotherapy may cause nausea and vomiting by release of serotonin in the small intestine. Ondansetron is a serotonin type 5-HT3 receptor antagonist that blocks the action of serotonin.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Ondansetron, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’s OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.